Varicella Zoster Encephalitis in an Immunocompetent Traveler

Main Article Content

Erika Yuki Mogami Bomfim
https://orcid.org/0009-0000-4732-5230
Bárbara Lopes da Silva
https://orcid.org/0009-0009-9826-4250
Carina Ferlin Saccomani Vilas Boas
https://orcid.org/0009-0008-5148-3491
Aimee Elizabeth Correa Alves de Mattos
https://orcid.org/0009-0003-2626-5381
Bárbara Redondo Shinoda
Ana Paula Rocha Veiga
Alexandre Ely Campeas

Abstract

Varicella-zoster virus (VZV) is a frequent cause of encephalitis in adults, particularly in elderly and immunocompromised individuals. In young immunocompetent patients without cutaneous manifestations, it represents a rare presentation. We report the case of a 35-year-old previously healthy man who developed VZV encephalitis during a ten-month trip across Latin America. While in Nicaragua, he presented with bitemporal and left suboccipital headache, pulsatile in nature, insidious in onset, daily, and with progressive worsening. After five days, he sought medical care due to language disturbance (paraphasia). He denied fever, seizures, paresis, or systemic symptoms. Physical examination revealed only language impairment, with no skin lesions. Magnetic resonance imaging demonstrated hyperintensity in the left temporal lobe. Cerebrospinal fluid analysis showed hypoglycorrhachia, hyperproteinorrhachia, and hyperlactatorrhachia. Molecular testing (PCR) detected VZV DNA. Intravenous acyclovir was initiated for eight days, followed by oral acyclovir for six days, resulting in complete resolution of symptoms without residual deficits. Investigation for immunodeficiency, including HIV testing, lymphocyte immunophenotyping, immunoglobulin levels, and complement assessment, was negative. As prophylaxis, vaccination with the recombinant inactivated herpes zoster vaccine was recommended. This case illustrates an atypical presentation of VZV encephalitis, reinforcing the importance of molecular testing in the investigation of acute neurological syndromes and of early antiviral treatment for a favorable prognosis.

Article Details

How to Cite
Bomfim, E. Y. M., Silva, B. L. da, Boas, C. F. S. V., Mattos, A. E. C. A. de, Shinoda, B. R., Veiga, A. P. R., & Campeas, A. E. (2026). Varicella Zoster Encephalitis in an Immunocompetent Traveler. Brazilian Journal of Case Reports, 6(1), bjcr155. https://doi.org/10.52600/2763-583X.bjcr.2026.6.1.bjcr155
Section
Clinical Case Reports
Author Biographies

Erika Yuki Mogami Bomfim, Emílio Ribas Institute of Infectious Diseases

Emílio Ribas Institute of Infectious Diseases, São Paulo, Brazil.

Bárbara Lopes da Silva, University of Taubaté (UNITAU)

University of Taubaté (UNITAU), Taubaté, São Paulo, Brazil.

Carina Ferlin Saccomani Vilas Boas, University of Taubaté (UNITAU)

University of Taubaté (UNITAU), Taubaté, São Paulo, Brazil.

Aimee Elizabeth Correa Alves de Mattos, University of Taubaté (UNITAU)

University of Taubaté (UNITAU), Taubaté, São Paulo, Brazil.

Bárbara Redondo Shinoda, Emílio Ribas Institute of Infectious Diseases

Emílio Ribas Institute of Infectious Diseases, São Paulo, Brazil.

Ana Paula Rocha Veiga, Emílio Ribas Institute of Infectious Diseases

Emílio Ribas Institute of Infectious Diseases, São Paulo, Brazil.

Alexandre Ely Campeas, Emílio Ribas Institute of Infectious Diseases

Emílio Ribas Institute of Infectious Diseases, São Paulo, Brazil.

University of Taubaté (UNITAU), Taubaté, São Paulo, Brazil.

References

Kennedy PGE. Varicella-zoster virus latency in human ganglia. Rev Med Virol. 2002;12(5):327–34. doi:10.1016/0022-3956(75)90026-6

Kennedy PGE, Gershon AA. Clinical features of varicella-zoster virus infection. Viruses. 2018;10(11):609. doi:10.3390/v10110609

George BP, Schneider EB, Venkatesan A. Encephalitis hospitalization rates and inpatient mortality in the United States, 2000–2010. PLoS One. 2014;9(9):e104169. doi:10.1371/journal.pone.0104169

Alvarez JC, Alvarez J, Ticono J, Medallo P, Miranda H, Ferrés M, et al. Varicella-zoster virus meningitis and encephalitis: an understated cause of central nervous system infections. Cureus. 2020;12(11):e11603. doi:10.7759/cureus.11583

Bodilsen J, Storgaard M, Larsen L, Wiese L, Helweg-Larsen J, Lebech AM, et al. Infectious meningitis and encephalitis in adults in Denmark: a prospective nationwide observational cohort study (DASGIB). Clin Microbiol Infect. 2018;24(10):1102.e1–5. doi:10.1016/j.cmi.2018.01.016

Picard L, Mailles A, Fillâtre P, Tattevin P, Stahl JP. Encephalitis in travellers: a prospective multicentre study. J Travel Med. 2023;30(2):taad013. doi:10.1093/jtm/taac145

Herlin LK, Hansen KS, Bodilsen J, Larsen L, Brandt C, Andersen CØ, et al. Varicella zoster virus encephalitis in Denmark from 2015 to 2019: a nationwide prospective cohort study. Clin Infect Dis. 2021;72(7):1192–9. doi:10.1093/cid/ciaa185

Chamizo FJ, Gilarranz R, Hernández M, Ramos D, Pena MJ. Central nervous system infections caused by varicella-zoster virus. J Neurovirol. 2016;22(4):529–32. doi:10.1007/s13365-016-0422-y

Lenfant T, L’Honneur AS, Ranque B, Pilmis B, Charlier C, Zuber M, et al. Neurological complications of varicella zoster virus reactivation: prognosis, diagnosis, and treatment of 72 patients with positive PCR in the cerebrospinal fluid. Brain Be-hav. 2022;12(2):e2496. doi:10.1002/brb3.2455

Pahud BA, Glaser CA, Dekker CL, Arvin AM, Schmid DS. Varicella zoster disease of the central nervous system: epidemio-logical, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis. 2011;203(3):316–23. doi:10.1093/infdis/jiq066

Kaewpoowat Q, Salazar L, Aguilera E, Wootton SH, Hasbun R. Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes. Infection. 2016;44(3):337–45. doi:10.1007/s15010-015-0867-6

Skripuletz T, Pars K, Schulte A, Schwenkenbecher P, Yildiz Ö, Ganzenmueller T, et al. Varicella zoster virus infections in neurological patients: a clinical study. BMC Infect Dis. 2018;18(1):238. doi:10.1186/s12879-018-3137-2

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98. doi:10.1016/0022-3956(75)90026-6

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. doi:10.1111/j.1532-5415.2005.53221.x

Goswami S, Goyal R, DeLury J. A possible case of varicella zoster virus (VZV) meningoencephalitis in an immunocompetent host. Cureus. 2022;14(7):e26597. doi:10.7759/cureus.26539

Robertson KM, Harvey CL, Cunningham JM. Acyclovir-induced neurotoxicity with a positive cerebrospinal fluid varicella zoster PCR result creating a management dilemma: a case report. J Med Case Rep. 2020;14(1):171. doi:10.1186/s13256-020-02498-3

Salvotti F, Trapletti S, Chiarini G, Castellano M, Muiesan ML. Atypical varicella-zoster virus reactivation: a case report. Eur J Case Rep Intern Med. 2023;10(9):003866. doi:10.12890/2023_003945

Ministério da Saúde (BR). Portaria SECTICS/MS nº 61, de 16 de dezembro de 2024. Torna pública a decisão de incorporar, no âmbito do Sistema Único de Saúde – SUS, o teste de PCR multiplex para agentes infecciosos de meningite e encefalite. Di-ário Oficial da União. Brasília (DF); 2024 dez 18 [citado 2025 out 7]. Disponível em: https://bvs.saude.gov.br/bvs/saudelegis/sctie/2024/prt0061_18_12_2024.html

Comissão Nacional de Incorporação de Tecnologias no SUS (CONITEC). Relatório de Recomendação nº 938: Teste PCR multiplex para diagnóstico de meningite e encefalite. Brasília (DF): Ministério da Saúde; 2024 [citado 2025 out 7]. Disponí-vel em: https://www.gov.br/conitec/pt-br/midias/relatorios/2024/relatorio-de-recomendacao-no-938_pcr-multiplex-meningite_encefalite.pdf

Agência Nacional de Saúde Suplementar (ANS). Resolução Normativa nº 627, de 14 de fevereiro de 2025. Atualiza o Rol de Procedimentos e Eventos em Saúde, incluindo o exame “Agentes infecciosos na encefalite e meningite – detecção por PCR multiplex em painel no líquor”. Diário Oficial da União. Brasília (DF); 2025 fev 17 [citado 2025 out 7]. Disponível em: https://www.gov.br/ans/pt-br/assuntos/gestao-da-saude/rol-de-procedimentos/.